Neurotoxicity after hematopoietic stem cell transplant in multiple sclerosis
Simon Thebault(University of Pennsylvania), Mark S. Freedman(University of Ottawa), Lisa A.S. Walker(University of Ottawa), Harold Atkins(University of Ottawa), Heather MacLean(University of Ottawa), Jason A. Berard(University of Ottawa), Gauruv Bose(University of Ottawa), Sridar Narayanan(Montreal Neurological Institute and Hospital), Mohammad Abdoli(University of Ottawa), Douglas L. Arnold(McGill University), Daniel Tessier(Montreal Neurological Institute and Hospital), Amit Bar‐Or(University of Pennsylvania), Vincent Tabard‐Cossa(University of Ottawa), Hyunwoo Lee(Princess Alexandra Hospital), Marjorie A. Bowman(United States Department of Veterans Affairs), Carolina Rush(University of Ottawa), Ronald A. Booth(University of Ottawa)
Cited by 34
Related Papers
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
|New England Journal of Medicine|2016|1.9k
Multiple sclerosis
|Nature Reviews Disease Primers|2018|1.4k